# KLOW Peptide Results in the Research Literature > KLOW results in the research literature: what the component studies measured, what the most recent 2024–2026 findings show, and the honest structural gap — no blend-level result exists. A component-by-component reading of what the published studies have actually measured — the recent results first, the honest absence named plainly. ## In plain English KLOW results in the research literature are, strictly speaking, four separate sets of results — one for each peptide component — not one unified set of blend-level results. No controlled study has ever measured outcomes for the KLOW four-peptide blend against a control, against monotherapy or against a subset. All combination result claims are extrapolations from single-component preclinical data. This page assembles the most important results from each arm's literature, names the most recent papers first, and holds the structural absence plainly: the result of testing the blend itself is an empty table. The component results are real and worth reading. The blend table is empty and that is also real. ## KPV results The foundational KPV result is from Dalmasso et al. 2008 [3]: nanomolar KPV (10 nM) inhibited NF-kappaB and MAP-kinase signaling and reduced TNF-alpha, IL-6, IL-1beta and IL-8 in human intestinal epithelial cells; oral KPV at 100 µM reduced DSS- and TNBS-induced colitis severity in C57BL/6 mice. PepT1 (SLC15A1) mediates uptake at a substrate Km of approximately 160 µM. The most recent KPV result: the 2024 PepT1-targeted nanodrug study [8] showed that co-assembly of KPV with FK506 into targeted nanoparticles improved both acute and chronic colitis in mice, restoring tight-junction proteins and reducing inflammatory cytokines beyond either agent alone — the most advanced demonstration to date of KPV's anti-inflammatory potential in a delivery-optimized context. For gut-delivery infrastructure, Laroui et al. 2010 [9] showed that polysaccharide-hydrogel-encapsulated nanoparticles delivered to the colon reduced colitis in mice, establishing the oral delivery strategy later adapted for KPV. ## GHK-Cu results GHK-Cu has the longest clinical data record in the blend. The 2015 Pickart et al. review [4] documents: collagen production increased in 70% of women treated with topical GHK-Cu versus 50% for vitamin C and 40% for retinoic acid; documented placebo-controlled improvements in skin laxity, clarity, fine lines, wrinkle depth and density. Plasma GHK declines from approximately 200 ng/mL at age 20 to approximately 80 ng/mL by age 60. The 2018 gene-expression analysis [5] showed GHK at 1–10 nM modulates approximately 31.2% of human genes at a 50%-or-greater change threshold, with strongest signals toward the ubiquitin-proteasome system (41 genes up), DNA-repair and antioxidant programs. Most recent GHK-Cu results: the 2025 Mao et al. colitis study [11] showed GHK-Cu reduced colonic damage and cytokines via SIRT1/STAT3 pathway suppression, restoring epithelial barrier function. The 2025 Mortazavi et al. anti-wrinkle delivery review [12] synthesizes topical GHK-Cu efficacy and the formulation/penetration challenge. Hair-follicle stimulation was reported for topical peptide-copper complexes in C3H mice [15]. ## BPC-157 results The canonical BPC-157 result is from Staresinic et al. 2003 [2]: intraperitoneal BPC-157 at 10 µg, 10 ng or 10 pg per Wistar rat accelerated healing of a fully transected Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte outgrowth in vitro. A 2006 follow-up [10] showed BPC-157 also promoted tendon-to-bone healing after Achilles detachment and counteracted corticosteroid impairment. Most recent BPC-157 results: the 2025 first-in-human IV safety pilot [6] — 10 mg day one, 20 mg day two in two healthy adults — found no adverse events and no measurable changes in safety biomarkers. Small n; not efficacy data. The 2026 Int J Mol Sci review [7] synthesizes the regenerative and analgesic findings and places analgesia as a primary theme of the accumulated record. ## TB-500 results The foundational result for the TB-500 arm is from Malinda et al. 1999 [1], using full-length thymosin beta-4: topical or intraperitoneal Tbeta4 increased rat full-thickness wound re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline; as little as 10 pg stimulated keratinocyte migration 2–3-fold in vitro; wound contraction increased ≥11% by day 7. Most recent result: Wei et al. 2024 [13] showed inhaled exogenous thymosin beta-4 suppressed bleomycin-induced pulmonary fibrosis in a preclinical model — extending the tissue-repair record from dermal wounds to lung. The 2026 Mendias and Awan sports-medicine review [14] concludes that unapproved peptides including TB-500 show animal-model promise but scarce rigorous human safety data, with potential for serious harm. The key caveat, restated: all significant TB-500 arm results are for the full-length 43-amino-acid native protein thymosin beta-4, not the short Ac-LKKTETQ TB-500 fragment. The fragment's efficacy relative to the native protein has not been formally established. ## The absent blend result No controlled study has tested the KLOW four-peptide blend. The KPV + GHK-Cu + BPC-157 + TB-500 combination has never appeared in a study design — no randomized trial, no animal model, no in-vitro experiment comparing the blend against monotherapy, against a three-peptide subset or against a vehicle control. The KLOW results table at the blend level is empty. This is the central fact. The component records are substantial; combining them in one vial does not generate blend-level evidence by extension. Whether the combination rationale holds — that four non-overlapping mechanism arms address complementary steps of the same cascade synergistically — remains an open experimental question. --- A composed scholarly record that reads four separate peptide literatures as four platinum facets of one tissue-repair cascade — the most recent component studies surfaced first and the blend's absent data held plainly in view.